Condition: Colon Cancer · dMMR Colorectal Cancer · Sponsor: University of Iowa
This is a Phase II, single arm study looking at the rate of major clinical response and non-operative management in Stage II and III colon cancer after 18 weeks (up to 6 cycles) of neoadjuvant dostarlimab.
This description comes directly from the study's public registry record.
Saima Sharif, MD, MS · 319-356-1616 · saima-sharif@uiowa.edu
Alisha Demsky · 319-384-5461 · alisha-demsky@uiowa.edu
Always discuss trial participation with your own doctor first.
| University of Iowa Hospitals & Clinics | Iowa City, Iowa, United States | Recruiting |
| University of Wisconsin | Madison, Wisconsin, United States | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT05239546